Joseph M. Casper was named Chief Operating Officer of NRX Pharmaceuticals, Inc., effective January 27, 2026. As of November 14, 2026, NRX Pharmaceuticals, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on February 2, 2026, naming 1 appointment (Form 8-K, February 2, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like NRX Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
NRX Pharmaceuticals, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-02-02. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as NRX Pharmaceuticals, Inc. files it.
Also on the record for NRX Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 15, 2026 | Stake report, Schedule 13G/A, by Anson Funds Management LP | 4.9% of the class | 5%+ stakes | Source |
| August 21, 2025 | Stake report, Schedule 13G, by The B Group, Inc. | 12.62% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Anson Funds Management LP | 9.3% of the class | 5%+ stakes | Source |
| March 7, 2025 | Form D, private offering | $3.50M sold | Form D page | Source |
Selling to them or working with them? See who runs NRX Pharmaceuticals, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on NRX Pharmaceuticals, Inc. and the records around it.
NRX Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings May 2026
- Who owns it
Companies that share a holder
- The B Group, Inc. also filed stake reports on 1 other company: Retension Pharmaceuticals, Inc. (Oct 2026)
- Anson Funds Management LP also filed stake reports on 36 other companies: 22nd Century Group, Inc. (Aug 2026), Imperial Petroleum Inc. (Aug 2026), K Wave Media Ltd. (Aug 2026)
Watch NRX Pharmaceuticals, Inc.
Get an email when NRX Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on NRX Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on NRX Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on NRX Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-02-02 | In | Chief Operating Officer | 2026-01-27 | 8-K, 2026-02-02 |
Who leads NRX Pharmaceuticals, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Operating Officer: Joseph M. Casper, appointed, effective 2026-01-27 (filed 2026-02-02).
New leaders reset buying decisions — get the Full Report on NRX Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Operating Officer at NRX Pharmaceuticals, Inc., with the record behind each one.
Find candidates like Chief Operating Officer at NRX Pharmaceuticals, Inc.Every change, in the filing's words
Appointed: Joseph M. Casper, Chief Operating Officer, effective 2026-01-27
On January 27, 2026, the Board of Directors of the Company appointed Joseph M. Casper, age 75, as the Chief Operating Officer of the Company, effective January 27, 2026.
- Mr. Casper brings 35 years of experience in the healthcare industry to the Company's leadership team.
- Prior to joining the Company, Mr. Casper has held various senior leadership positions.
- Mr. Casper has served in consulting leadership positions with Deloitte and First Consulting Group, where he advised large organizations and academic medical centers.
- His professional experience also includes work with major payer and provider organizations, including Kaiser Permanente and Anthem.
- He also worked extensively with academic medical centers such as the University Medical Center, Cleveland, Ohio.
- Mr. Casper is the co-inventor of an early medical record aggregation platform that ultimately scaled to serve more than 15 million patients.
- Between 2016 to 2021, he served on the board of directors of Ingine Inc., a healthcare artificial intelligence company.
- Since 2019, he has been serving on the board of directors of ThriveWell Tech, a company focused on senior living technologies.
- Further, since 2021, he has been serving on the board of directors of Touro University, supporting physician and nursing education through its Colleges of Osteopathic Medicine and Health and Human Services.
Tools for this story
Each opens in a new tab, filled in for NRX Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
